Table 1.
The demographic characteristics of the enrolled PMP patients.
| Median (Q1–Q3)/N (%) | ||
|---|---|---|
| Age, years | 58.00 (49.00–64.50) | |
| Gender | Male | 191 (37.30) |
| Female | 321 (62.70) | |
| Serum CA125, U/ml | ≤35 | 229 (44.73) |
| >35 | 283 (55.27) | |
| Serum CEA, ng/ml | ≤5 | 160 (31.25) |
| >5 | 352 (68.75) | |
| Serum CA19-9, U/ml | ≤30 | 268 (52.34) |
| >30 | 244 (47.66) | |
| Serum CA724 | ≤12 | 170 (33.20) |
| >12 | 343 (66.80) | |
| Serum CA242 | ≤20 | 227 (44.34) |
| >20 | 285 (55.66) | |
| Abnormal number of serum biomarkers | 0–1 | 129 (25.20) |
| 2–3 | 132 (25.78) | |
| 4–5 | 251 (49.02) | |
| Ascites CA125, U/ml | ≤35 | 281 (54.88) |
| >35 | 231 (45.12) | |
| Ascites CEA, ng/ml | ≤5 | 296 (57.81) |
| >5 | 216 (42.19) | |
| Ascites CA19-9, U/ml | ≤30 | 313 (61.13) |
| >30 | 199 (38.87) | |
| Ascites CA724 | ≤12 | 315 (61.52) |
| >12 | 197 (38.48) | |
| Ascites CA242 | ≤20 | 339 (66.21) |
| >20 | 173 (33.79) | |
| Abnormal number of ascites biomarkers | 0–1 | 284 (55.47) |
| 2–3 | 47 (9.18) | |
| 4–5 | 181 (35.35) | |
| PCI | 25.00 (13.00–32.00) | |
| PCI < 10 | 110 (21.48) | |
| 10 ≤ PCI ≤ 20 | 68 (13.28) | |
| PCI > 20 | 334 (65.23) | |
| CC scores | CC 0–1 | 253 (49.41) |
| CC 2–3 | 259 (50.59) | |
| HIPEC | Yes | 442 (86.33) |
| No | 70 (13.67) | |
| Origin | Appendix | 486 (94.92) |
| Others | 26 (5.08) | |
| Pathology | Low-grade | 353 (68.95) |
| High-grade | 159 (31.05) |
CA, cancer antigen; CC, completeness of cytoreduction; CEA, carcinoembryonic antigen; HIPEC, hyperthermic intraperitoneal chemotherapy; PCI, peritoneal cancer index; PMP, pseudomyxoma peritonei.